Is RPRX or RZLT more undervalued in 2026?

CirclFi compares Royalty Pharma plc (RPRX) and Rezolute, Inc. (RZLT) using 13 institutional-grade valuation models. RPRX has a Quality of Company score of 8.4/10 while RZLT scores 4.0/10.

Which is a better buy — RPRX or RZLT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RPRX and RZLT valuations compare?

RPRX at $54.48 and RZLT at $3.27 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RPRX vs RZLT Valuation Comparison 2026 — Intrinsic Value Analysis

RPRX

Biotechnology

Royalty Pharma plc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$54.48

Last close

Models

12/13

Active

RZLT

Biotechnology

Rezolute, Inc.

Quality

4.0

out of 10

Value Trap

LOW

Price

$3.27

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	RPRX Fair Value	RPRX Upside	RZLT Fair Value	RZLT Upside
Bayesian DCF	Intrinsic	$57.58	+5.7%	$0.94	-71.4%
Earnings Power Value	Intrinsic	$1.77	-96.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$1.46	-55.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RPRX vs RZLT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RPRX vs RZLT — Which Stock Is More Undervalued?

RPRX scores higher with a 8.4/10 quality rating vs RZLT's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Royalty Pharma plc (RPRX) and Rezolute, Inc. (RZLT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RPRX currently trades at $54.48 with a QOC of 8.4/10, while RZLT trades at $3.27 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).